Mirikizumab
- Generic Name
- Mirikizumab
- Brand Names
- Omvoh
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1884201-71-1
- Unique Ingredient Identifier
- Z7HVY03PHP
- Background
Mirikizumab is a monoclonal antibody developed by Eli Lilly intended to treat ulcerative colitis. It inhibits the actions of interleukin-23 (IL-23), a pro-inflammatory cytokine that activates pathways contributing to the development of inflammatory diseases.
...
- Indication
Mirikizumab is indicated for the treatment of adult patients with moderate-to-severely active ulcerative colitis.
- Associated Conditions
- Moderately to Severely Active Ulcerative Colitis
- Associated Therapies
- -
A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1158
- Registration Number
- NCT03926130
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸Digestive Health Specialists, Tupelo, Mississippi, United States
🇺🇸GastroIntestinal Biosciences Clinical Trials, Los Angeles, California, United States
A Study of Mirikizumab in Participants With Plaque Psoriasis
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 29
- Registration Number
- NCT03718884
- Locations
- 🇺🇸
High Point Clinical Trials Center, High Point, North Carolina, United States
🇺🇸Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸Avail Clinical Research LLC, DeLand, Florida, United States
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
- First Posted Date
- 2018-06-14
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1936
- Registration Number
- NCT03556202
- Locations
- 🇺🇸
Modern Research Associates, Dallas, Texas, United States
🇺🇸Univ of Connecticut, Farmington, Connecticut, United States
🇺🇸Dermatologic Surgery Specialists, PC, Macon, Georgia, United States
A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)
- First Posted Date
- 2018-05-24
- Last Posted Date
- 2021-03-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1484
- Registration Number
- NCT03535194
- Locations
- 🇦🇺
Clinical Trials SA Pty Ltd, Adelaide, South Australia, Australia
🇺🇸Dawes Fretzin Clinical Research, Indianapolis, Indiana, United States
🇺🇸Dermatology Associates, Seattle, Washington, United States
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
- First Posted Date
- 2018-05-09
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1063
- Registration Number
- NCT03519945
- Locations
- 🇺🇸
University of California San Diego, La Jolla, California, United States
🇺🇸Grand Teton Research Group, Idaho Falls, Idaho, United States
🇺🇸NYU Langone Long Island Clinical Research Associates, Great Neck, New York, United States
An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
- First Posted Date
- 2018-05-08
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1281
- Registration Number
- NCT03518086
- Locations
- 🇺🇸
Gastroenterology Consultants of Clearwater, Clearwater, Florida, United States
🇺🇸Clinical Research of West Florida, Inc. (Clearwater), Clearwater, Florida, United States
🇮🇳Poona Medical Foundation. Ruby Hall Clinic, Pune, Maharashtra, India
A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2020-09-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 530
- Registration Number
- NCT03482011
- Locations
- 🇺🇸
The South Bend Clinic, South Bend, Indiana, United States
🇲🇽B&B Investigaciones Medicas, SC, Mazatlan, Sinaloa, Mexico
🇰🇷Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of
A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2016-09-14
- Last Posted Date
- 2020-06-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 205
- Registration Number
- NCT02899988
- Locations
- 🇺🇸
Renstar Medical Research, Ocala, Florida, United States
🇺🇸Forward Clinical Trials, Inc, Tampa, Florida, United States
🇵🇷Grupo Dermatologico de Carolina, Carolina, Puerto Rico
A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease
- First Posted Date
- 2016-09-07
- Last Posted Date
- 2022-08-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 191
- Registration Number
- NCT02891226
- Locations
- 🇺🇸
Digestive Healthcare of Georgia, Atlanta, Georgia, United States
🇺🇸Virginia Mason Medical Center, Seattle, Washington, United States
🇺🇸University of Washington Medical Center, Seattle, Washington, United States
A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis
- First Posted Date
- 2015-10-28
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 249
- Registration Number
- NCT02589665
- Locations
- 🇺🇸
Minnesota Gastroenterology, P.A., Plymouth, Minnesota, United States
🇺🇸Carolinas Healthcare System, Charlotte, North Carolina, United States
🇺🇸Borland Groover Clinic, Jacksonville, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.